TAGRISSO (osimertinib)

TAGRISSO is an EGFR TKI indicated as a monotherapy for:

Second-line TAGRISSO

Baseline characteristics

TAGRISSO was studied across a broad population of NSCLC patients in AURA3:9

Demographic and clinical characteristics of patients at baseline:9,11

Of the 1036 patients screened at baseline, 419 underwent randomisation. Study baseline characteristics included:9

Exclusion criteria
Exclusion criteria